Back

The effect of tafamidis treatment on cardiovascular aging in patients with Transthyretin cardiomyopathy. An observational study.

27 August 2023 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Heart disease in the elderly: treatment and outcomes Cardiovascular Disease in the Elderly ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Dimitrios Delialis

Alexandra University Hospital, Athens (Greece)

6 More presentations in this session

Presentation thumbnail
Potential cardioprotective effects of acetylcholinesterase inhibitors in patients with Alzheimer's disease
Doctor L. Rampa (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Age disparity among severe aortic stenosis patients: AVR treatment rates and clinical outcomes among octogenarians
Mr O. Shimoni (IL)
Abstract Slides Video
Presentation thumbnail
Outcomes of catheter ablation for ventricular tachycardia in the geriatric population
Doctor G. Kowlgi (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Short and long-term renal function changes with direct oral anticoagulants in elderly patients with atrial fibrillation
Doctor G. Armentaro (Catanzaro, IT)
Abstract Slides Video
Presentation thumbnail
Adverse cardiovascular outcomes and sex-specific differences among older adults with cardiac ageing
Associate Professor R. Tan (Singapore, SG)
Abstract Slides Video

Access the full session

Session thumbnail
Heart disease in the elderly: treatment and outcomes

The Event

Event poster

ESC Congress 2023

27 August 2023 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Natural course and effect of tafamidis treatment in real-life octogenarians with wild-type transthyretin cardiac amyloidosis: an international multi-centre analysis.
thumbnail
Congress Presentation
Impact of Tafamidis on survival in elderly patients in a real-world setting: insights from the Healthcare European Amyloidosis Registry
thumbnail
Congress Presentation
A biopsy-based pilot clinical study: monitoring the effectiveness of tafamidis treatment of patients with transthyretin amyloid cardiomyopathy.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources